



一期臨床研究中心
Phase 1 Clinical Trial Centre

Oncology focus



CUHK Phase 1 Clinical Trial Centre

The CUHK P1CTC provides investigators and industry with resources, information and expertise in early drug development especially on early phase clinical research in order to foster and facilitate the clinical research enterprise within the CUHK and the broader clinical research community including global and local biotechnology and pharmaceutical companies. The Centre, located within the Prince of Wales Hospital premise, can cater up to 26 subjects at any one time for day- or overnight witnessed dosing, observation and procedures, supported by a core team of experienced physicians, nurses and pharmacists. The Centre is serviced by the Biomedical and Bio-analytical Mass Spectrometry Laboratory of the Department of Chemical Pathology with allocated manpower to support measurements of drugs and metabolites including assay development and analytical work.

To date, the Centre has evaluated compounds of a wide range of therapeutic areas including oncology, hepatology, endocrinology, cardiology, gastroenterology, haematology, neuropathy and respiratory medicine. Additionally, the Centre seeks to propagate the appropriate and safe application of Traditional Chinese Medicine (TCM) in needed population and is now embarking on early phase clinical studies to determine the pharmacokinetics and pharmacodynamics of TCM. Identification of suitable subjects is facilitated by our growing pool of healthy volunteers now reaching over 7,500 people as well as our close connection with our clinical partners who have access to patients who may be eligible. Innovation and technology are championed as an important area of development and the Government of the Hong Kong Special Administrative Region has made substantial investments including liberalising research funding opportunities to accelerate life science discoveries and to enhance the local research ecosystem. The cutting-edge facilities and expertise offered by the Centre contribute to promoting Hong Kong as a hub of biomedical excellence as we maintain our leadership in translational research.

Dear Doctor/ Oncologist,

Your support is important to us and we hope to keep you in touch with our early-phase oncology research activities and facilitate the referral process. Please feel free to contact us if you are interested in referring patients to any of our studies.

Current early-phase studies

Title	Type of Study	PI/ contract	Disease sites
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer	1	Herbert Loong (h_loong@clo.cuhk.edu.hk)	NSCLC, Medullary Thyroid Cancer, Colon Cancer, Solid Tumor
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	1	Herbert Loong (h_loong@clo.cuhk.edu.hk)	Lung
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms	1	Herbert Loong (h_loong@clo.cuhk.edu.hk)	Advanced solid tumors Hematologic neoplasms
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	1	Herbert Loong (h_loong@clo.cuhk.edu.hk)	Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase Ib Study of TNO155 in Combination With Spaltalizumab or Ribociclib in Selected Malignancies	1	Brigitte Ma (brigitte@clo.cuhk.edu.hk)	NSCLC, HNSCC, ESCC, GIST, CRC
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC)	1	Brigitte Ma (brigitte@clo.cuhk.edu.hk)	TNBC
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.	1	Brigitte Ma (brigitte@clo.cuhk.edu.hk)	NSCLC, Melanoma, NPC, MSS-CRC, TNBC
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies	1,2	Brigitte Ma (brigitte@clo.cuhk.edu.hk)	NPC, ovary, lymphoma, Prostate. C
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies	2	Brigitte Ma (brigitte@clo.cuhk.edu.hk)	TNBC, Pancreas, Melanoma, Endometrium
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies	2	Herbert Loong (h_loong@clo.cuhk.edu.hk)	Various Cancer Types

You are encouraged to contact the PI (see email above) or Phase 1 Clinical Trial Centre (p1ctc@cuhk.edu.hk) before making a medical referral. For details about inclusion criteria of each study, please refer to <http://www.clo.cuhk.edu.hk/eng/comprehensive-cancer-trials-unit/current-trials/> .

Contact Us

11EF, Special Block (Wing E,F), Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong
Website: www.p1ctc.med.cuhk.edu.hk/ Email: p1ctc@cuhk.edu.hk